Purpose
This study aimed to analyze dementia-related death statistics in Korea between 2013 and 2023.
Methods
The analysis utilized microdata from Statistics Korea’s cause-of-death statistics. Among all recorded deaths, those related to dementia were extracted and analyzed using the underlying cause-of-death codes from the International Classification of Diseases, 10th revision.
Results
The number of dementia-related deaths increased from 8,688 in 2013 to 14,402 in 2023. The crude death rate rose from 17.2 per 100,000 in 2013 to 28.2 per 100,000 in 2023, although the age-standardized death rate declined from 9.7 to 8.7 over the same period. The dementia death rate is 2.1 times higher in women than in men, and mortality among individuals aged 85 and older exceeds 976 per 100,000. By specific cause, Alzheimer’s disease accounted for 77.1% of all dementia deaths, and by place, the majority occurred in hospitals (76.2%), followed by residential institutions including nursing homes (15.3%) in 2023.
Conclusion
The rising mortality associated with dementia, especially Alzheimer’s disease, highlights a growing public health concern in Korea. These findings support the need for enhanced prevention efforts, improved quality of care, and targeted policies addressing the complexities of dementia management. It is anticipated that this empirical analysis will contribute to reducing the social burden.

ABSTRACT

Alzheimer disease (AD) is a common neurodegenerative disorder, characterized by memory impairment, dementia, and diminished cognitive function. This disease affects more than 20 million people worldwide. Amyloid beta (Aβ) plaques and neurofibrillary tangles (NFTs) are important pathological markers of AD. Multiple studies have indicated a potential association between elevated cholesterol levels and increased risk of AD, suggesting that lowering the cholesterol level could be a viable strategy for AD treatment or prevention. Statins, potent inhibitors of cholesterol synthesis, are widely used in clinical practice to decrease the plasma levels of LDL cholesterol in patients with hyperlipidemia. Statins are known to play a neuroprotective role in limiting Aβ pathology through cholesterol-lowering therapies. In addition to Aβ plaques and neurofibrillary tangles, the brains of AD patients exhibit signs of oxidative stress, neuroinflammatory responses, and synaptic disruption. Consequently, compounds with antioxidant, anti-inflammatory, and/or neuroprotective properties could be beneficial components of AD treatment strategies. In addition to lowering LDL cholesterol, statins have demonstrated therapeutic efficacy in various forms, including antioxidant, anti-inflammatory, and neuroprotective effects. These properties of statins are potential mechanisms underlying their beneficial effects in treating neurodegenerative diseases. Therefore, this review was conducted to provide an overview of the protective effects of statins against AD.

Citations

• Advances in Alzheimer's disease: A multifaceted review of potential therapies and diagnostic techniques for early detection
  Monika Sharma, Pankaj Pal, Sukesh Kumar Gupta
  Neurochemistry International.2024; 177: 105761.     CrossRef